Renal Versus Extrarenal Activation of Vitamin D in Relation to Atherosclerosis, Arterial Stiffening, and Hypertension

American Journal of Hypertension

Volumn 20, Issue 9, 2007, Pages 1007-1015

  Richart, Tom ^a   Li, Yan ^b   Staessen, Jan A ^a  

^a Studies Coordinating Centre   (Belgium)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

arterial stiffening; atherosclerosis; chronic inflammatory disease; hypertension; macrophages; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; COLECALCIFEROL RECEPTOR; OXYGENASE; PLACEBO; VITAMIN D;

ARTERY CALCIFICATION; ARTERY INJURY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BONE MINERAL; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM URINE LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME REPRESSION; FEEDBACK SYSTEM; HUMAN; KIDNEY TUBULE CELL; MACROPHAGE; NONHUMAN; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTOLIC HYPERTENSION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CHOLECALCIFEROL; ELASTICITY; HUMANS; HYPERTENSION; KIDNEY; MUSCLE, SMOOTH, VASCULAR;

EID: 34548191441     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.03.017     Document Type: Review

References (82)

1. Norman P.E., and Powell J.T. Vitamin D: shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol 25 (2005) 39-46
2. Kesteloot H., and Geboers J. Calcium and blood pressure. Lancet 319 (2006) 813-815
3. Resnick L.M. Calciotropic hormones in human and experimental hypertension. Am J Hypertens 3 Suppl (1990) 171S-178S
4. Resnick L.M., Nicholson J.P., and Laragh J.H. Calcium metabolism in essential hypertension: relationship to altered renin system activity. Fed Proc 45 (1986) 2739-2745
5. Resnick L.M. The role of dietary calcium in hypertension: a hierarchical overview. Am J Hypertens 12 (1999) 99-112
6. Townsend M.S., Fulgoni III V.L., Stern J.S., Adu-Afarwuah S., and McCarron D.A. Low mineral intake is associated with high systolic blood pressure in the Third and Fourth National Health and Nutrition Examination Surveys: could we all be right?. Am J Hypertens 18 (2005) 261-269
7. Jorde R., and Bønaa K.H. Calcium from dairy products, vitamin D intake, and blood pressure: the Tromsø Study. Am J Clin Nutr 71 (2000) 1530-1535
8. Forman J.P., Bischoff-Ferrari H.A., Willett W.C., Stampfer M.J., and Curhan G.C. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 46 (2005) 676-682
9. Koshiyama H., Ogawa Y., Tanaka K., and Tanaka I. The unified hypothesis of interactions among the bone, adipose and vascular systems: "osteo-lipo-vascular interactions.". Med Hypotheses 66 (2006) 960-963
10. McCarron D.A., and Heaney R.P. Estimated healthcare savings associated with adequate dairy food intake. Am J Hypertens 17 (2004) 88-97
11. Hirose K., Tomiyama H., Okazaki R., Arai T., Koji Y., Zaydun G., Hori S., and Yamashina A. Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab 88 (2003) 2573-2578
12. Jørgensen L., Joakimsen O., Rosvold Berntsen G.K., Heuch I., and Jacobsen B.K. Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am J Epidemiol 160 (2004) 549-556
13. Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., and Wilson P.W. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Res 68 (2004) 271-276
14. Cappuccio F.P., Meilahn E., Zmuda J.M., and Cauley J.A. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 354 (1999) 971-975
15. Arad Y., Spadaro L.A., Roth M., Scordo J., Goodman K., Sherman S., Lerner G., Newstein D., and Guerci A.D. Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study. Coron Artery Dis 9 (1998) 513-518
16. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., and Demer L.L. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
17. 3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 96 (1997) 1477-1481
18. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol 35 (2000) 287-296
19. Kieffer P., Robert A., Capdeville-Atkinson C., Atkinson J., and Lartaud-Idjouadiene I. Age-related arterial calcifications in rats. Life Sci 66 (2000) 2371-2381
20. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86 (2001) 1633-1637
21. Prosser D.E., and Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29 (2004) 664-673
22. Lal H., Pandey R., and Aggarwal S.K. Vitamin D: non-skeletal actions and effects on growth. (Abstract). Nutr Res 19 (1999) 1683-1718
23. Zehnder D., and Hewison M. The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. Mol Cell Endocrinol 151 (1999) 213-220
24. Rittie L., and Fisher G.J. UV-light-induced signal cascades and skin aging. Ageing Res Rev 1 (2002) 705-720
25. Clemens T.L., Zhou X.Y., Myles M., Endres D., and Lindsay R. Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab 63 (1986) 656-660
26. Kerr D.N.S. Hypercalcemia and metastatic calcification. Cardiovasc Res 36 (1997) 293-297
27. 3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci 70 (2002) 1777-1788
28. Price P.A., Buckley J.R., and Williamson M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131 (2001) 2910-2915
29. Price P.A., Faus S.A., and Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21 (2001) 817-824
30. Dao H.H., Essalihi R., Bouvet C., and Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 66 (2005) 307-317
31. Marche P., Hérembert T., and Zhu D.L. Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy. Int J Cardiol 62 Suppl 2 (1997) S17-S22
32. Hewison M., Zehnder D., Bland R., and Stewart P.M. 1alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 25 (2000) 141-148
33. Hewison M., Zehnder D., Chakraverty R., and Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 215 (2004) 31-38
34. Holick M.F. Vitamin D: a millennium perspective. J Cell Biochem 88 (2003) 296-307
35. Holick M.F. Evolutionary biology and pathology of vitamin D. J Nutr Sci Vitaminol (Tokyo) (1992) 79-83 Spec No
36. Stern P.H., De O.J., and Bell N.H. Evidence for abnormal regulation of circulating 1 alpha,25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest 66 (1980) 852-855
37. 3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 161 (1985) 755-765
38. 3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 60 (1985) 960-966
39. 3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 72 (1983) 1856-1860
40. Bosch X., Lopez-Soto A., Morello A., Olmo A., and Urbano-Marquez A. Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Mayo Clin Proc 72 (1997) 440-444
41. Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. Gastroenterology 114 (1998) 1061-1065
42. Lichtenstein G.R. Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. Am J Gastroenterol 98 Suppl (2003) S24-S30
43. Cuffari C., and Lichtenstein G.R. Evaluation of bone mineral density in patients with inflammatory bowel disease. Curr Gastroenterol Rep 5 (2003) 261-262
44. Abreu M.T., Kantorovich V., Vasiliauskas E.A., Gruntmanis U., Matuk R., Daigle K., Chen S., Zehnder D., Lin Y.C., Yang H., Hewison M., and Adams J.S. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53 (2004) 1129-1136
45. Brooke B.S., Karnik S.K., and Li D.Y. Extracellular matrix in vascular morphogenesis and disease: structure versus signal. Trends Cell Biol 13 (2003) 51-56
46. Karnik S.K., Wythe J.D., Sorensen L., Brooke B.S., Urness L.D., and Li D.Y. Elastin induces myofibrillogenesis via a specific domain, VGVAPG. Matrix Biol 22 (2003) 409-425
47. 3 in vascular smooth muscle. Steroids 61 (1996) 657-663
48. 3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 (1998) 1302-1306
49. 3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 398 (2002) 1-6
50. 3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 91 (2002) 17-24
51. 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 (2002) 229-238
52. 3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 96 (2005) 59-66
53. Klar J., Sigl M., Obermayer B., Schweda F., Kramer B.K., and Kurtz A. Calcium inhibits renin gene expression by transcriptional and posttranscriptional mechanisms. Hypertension 46 (2005) 1340-1346
54. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., and Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8 (1995) 894-901
55. Staessen J., Sartor F., Roels H., Bulpitt C.J., Claeys F., Ducoffre G., Fagard R., Lauwerys R., Lijnen P., Rondia D., Thijs L., and Amery A. The associations between blood pressure, calcium, and other divalent cations: a population study. J Hum Hypertens 5 (1991) 485-494
56. McCarron D.A., and Reusser M.E. Are low intakes of calcium and potassium important causes of cardiovascular disease?. Am J Hypertens 14 Suppl (2001) 206S-212S
57. Resnick L.M., and Laragh J.H. Renin, calcium metabolism and the pathophysiologic basis of antihypertensive therapy. Am J Cardiol 56 (1985) 68H-74H
58. Resnick L.M., Muller F.B., and Laragh J.H. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 105 (1986) 649-654
59. Shan J., Resnick L.M., Lewanczuk R.Z., Karpinski E., Li B., and Pang P.K. 1,25-dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. Am J Hypertens 6 (1993) 983-988
60. Burgess E.D., Hawkins R.G., and Watanabe M. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens 3 (1990) 903-905
61. Lucas R.M., and Ponsonby A.L. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation?. Prog Biophys Mol Biol 92 (2006) 140-149
62. Smith S.J., Hayes M.E., Selby P.L., and Mawer E.B. Autocrine control of vitamin D metabolism in synovial cells from arthritic patients. Ann Rheum Dis 58 (1999) 372-378
63. 3). A double-blind, placebo-controlled study. Exp Clin Endocrinol 99 (1992) 151-153
64. Lind L., Pollare T., Hvarfner A., Lithell H., Sorensen O.H., and Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 11 (1989) 141-147
65. Lind L., Wengle B., Wide L., and Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 2 (1989) 20-25
66. Hingorani A., and Humphries S. Nature's randomised trials. Lancet 366 (2005) 1906-1908
67. Zebekakis P.E., Nawrot T., Thijs L., Balkestein E.J., van der Heijden-Spek J., Van Bortel L., Struijker-Boudier H.A., Safar M.E., and Staessen J.A. Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens 23 (2005) 1839-1846
68. Zmuda J.M., Cauley J.A., and Ferrell R.E. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 22 (2000) 203-217
69. Atwood L.D., Samollow P.B., Hixson J.E., Stern M.P., and MacCluer J.W. Genome-wide linkage analysis of blood pressure in Mexican Americans. Genet Epidemiol 20 (2001) 373-382
70. Cooper R.S., Luke A., Zhu X., Kan D., Adeyemo A., Rorimi C., Bouzekri N., and Ward R. Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19. Hypertension 40 (2002) 629-633
71. Krushkal J., Ferrell R., Mockrin S.C., Turner S.T., Sing C.F., and Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 99 (1999) 1407-1410
72. Cheng L.S., Davis R.C., Raffel L.J., Xiang A.H., Wang N., Quinones M., Wen P.Z., Toscano E., Diaz J., Pressman S., Henderson P.C., Azen S.P., Hsueh W.A., Buchanan T.A., and Rotter J.I. Coincident linkage of fasting plasma insulin and blood pressure to chromosome 7q in hypertensive Hispanic families. Circulation 104 (2001) 1255-1260
73. Hunt S.C., Ellison R.C., Atwood L.D., Pankow J.S., Province M.A., and Leppert M.F. Genome scans for blood pressure and hypertension. The National Heart, Lung, and Blood Institute Family Heart Study. Hypertension 40 (2002) 1-6
74. von Wowern F., Bengtsson K., Lindgren C.M., Orho-Melander M., Fyhrquist F., Lindblad U., Råstam L., Forsblom C., Kanninen T., Almgren P., Burri P., Katzman P., Groop L., Hulthén U.L., and Melander O. A genome wide scan for early onset primary hypertension in Scandinavians. Hum Mol Genet 12 (2003) 2077-2081
75. Muray S., Parisi E., Cardus A., Craver L., and Fernandez E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J Hypertens 21 (2003) 2069-2075
76. Ortlepp J.R., Krantz C., Kimmel M., von Korff A., Vesper K., Schmitz F., Mevissen V., Janssens U., Franke A., Hanrath P., Zerres K., and Hoffmann R. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. Int J Cardiol 105 (2005) 90-95
77. Ortlepp J.R., Lauscher J., Hoffmann R., Hanrath P., and Joost H.G. The vitamin D receptor gene variant is associated with the prevalence of Type 2 diabetes mellitus and coronary artery disease. Diabetes Med 18 (2001) 842-845
78. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., and Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85 (2001) 635-638
79. Vieth R., Pinto T.R., Reen B.S., and Wong M.M. Vitamin D poisoning by table sugar. Lancet 359 (2002) 672
80. Jacobus C.H., Holick M.F., Shao Q., Chen T.C., Holm I.A., Kolodny J.M., Fuleihan G.E., and Seely E.W. Hypervitaminosis D associated with drinking milk. N Engl J Med 326 (1992) 1213-1215
81. Vieth R., and Fraser D. Vitamin D insufficiency: no recommended dietary allowance exists for this nutrient. Can Med Assoc J 166 (2002) 1541-1542
82. Camp N.J., Hopkins P.N., Hasstedt S.J., Coon H., Malhotra A., Cawthon R.M., and Hunt S.C. Genome-wide multipoint parametric linkage analysis of pulse pressure in large, extended Utah pedigrees. Hypertension 42 (2003) 322-328